Flezurafenib

Flezurafenib
Clinical data
Other names	JZP-815
Identifiers
	IUPAC name 5-[[(3S)-3-[5-(4-fluorophenyl)-1H-imidazol-2-yl]-3,4-dihydro-2H-chromen-6-yl]oxy]-3,4-dihydro-1H-1,8-naphthyridin-2-one;
CAS Number	2760321-00-2;
PubChem CID	162772363;
IUPHAR/BPS	13233;
UNII	P26TTM6U27;
KEGG	D13132;
Chemical and physical data
Formula	C26H21FN4O3
Molar mass	456.477 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1CC(=O)NC2=NC=CC(=C21)OC3=CC4=C(C=C3)OC[C@@H](C4)C5=NC=C(N5)C6=CC=C(C=C6)F;
	InChI InChI=InChI=1S/C26H21FN4O3/c27-18-3-1-15(2-4-18)21-13-29-25(30-21)17-11-16-12-19(5-7-22(16)33-14-17)34-23-9-10-28-26-20(23)6-8-24(32)31-26/h1-5,7,9-10,12-13,17H,6,8,11,14H2,(H,29,30)(H,28,31,32)/t17-/m1/s1; Key:TWJSMWXWCWQPRO-QGZVFWFLSA-N;

Flezurafenib is an investigational new drug that is being evaluated by Jazz Pharmaceuticals for the treatment of cancers that are driven by oncogenic mutations that activate the RAS-RAF-MAPK signaling pathway. It acts as a rapidly accelerated fibrosarcoma (RAF) kinase inhibitor. ^[1]^[2] As of January 2025, flezurafenib has reached Phase 1 clinical trials, where it is being evaluated for the treatment of advanced solid tumors.^[1]

References

1 2 "JZP-815". PatSnap.
↑ Riaud M, Maxwell J, Soria-Bretones I, Dankner M, Li M, Rose AA (February 2024). "The role of CRAF in cancer progression: from molecular mechanisms to precision therapies". Nature Reviews. Cancer. 24 (2): 105–122. doi:10.1038/s41568-023-00650-x. PMID 38195917.